tetano
Editor, Senior Moderator
Int J Infect Dis
. 2022 Nov 30;S1201-9712(22)00624-5.
doi: 10.1016/j.ijid.2022.11.035. Online ahead of print.
Effectiveness of COVID-19 Vaccines in People Living with HIV in British Columbia and comparisons with a matched HIV-Negative Cohort: A Test Negative Design
Adeleke Fowokan[SUP] 1 [/SUP], Hasina Samji[SUP] 2 [/SUP], Joseph Puyat[SUP] 3 [/SUP], Naveed Janjua[SUP] 4 [/SUP], James Wilton[SUP] 1 [/SUP], Jason Wong[SUP] 4 [/SUP], Troy Grennan[SUP] 4 [/SUP], Catherine Chambers[SUP] 5 [/SUP], Abigail Kroch[SUP] 6 [/SUP], Cecilia T Costiniuk[SUP] 7 [/SUP], Curtis L Cooper[SUP] 8 [/SUP], Ann N Burchell[SUP] 9 [/SUP], Aslam Anis[SUP] 10 [/SUP]
Affiliations
Abstract
Background: We estimated the effectiveness of COVID-19 vaccines against laboratory-confirmed SARS-CoV-2 infection among people living with HIV (PLWH) and compared estimates with a matched HIV-negative cohort.
Method: We used the British Columbia COVID-19 Cohort, a population-based data platform which integrates COVID-19 data on SARS-CoV-2 tests, laboratory-confirmed cases, and immunizations with provincial health services data. Vaccine effectiveness (VE) was estimated with a test-negative design using multivariable logistic regression.
Results: Adjusted VE against SARS-CoV-2 infection was 79.2% (52.5, 90.9%) 7-59 days after two doses, rising to 91.6% (75.2, 97.2%) between 60-89 days. VE was preserved four to six months following receipt of 2 doses after which slight waning was observed (72.7% [39.1, 87.8%]). In the matched cohort (n=375 043), VE peaked at 91.0% (90.5, 91.5%) 7-59 days after 2 doses and was sustained for up to four months after which evidence of waning was observed, dropping to 83.8% (82.9, 84.7%) between four to six months.
Conclusion: Receipt of two COVID-19 vaccines doses was effective against SARS-CoV-2 infection among PLWH pre-Omicron. VE estimates appeared to peak later in PLWH compared to the matched HIV-negative cohort and the degree of waning was relatively quicker in PLWH; however, overall estimates were comparable in both populations.
Keywords: Canada; Coronavirus disease; HIV; SARS-CoV-2; Vaccine Effectiveness.
. 2022 Nov 30;S1201-9712(22)00624-5.
doi: 10.1016/j.ijid.2022.11.035. Online ahead of print.
Effectiveness of COVID-19 Vaccines in People Living with HIV in British Columbia and comparisons with a matched HIV-Negative Cohort: A Test Negative Design
Adeleke Fowokan[SUP] 1 [/SUP], Hasina Samji[SUP] 2 [/SUP], Joseph Puyat[SUP] 3 [/SUP], Naveed Janjua[SUP] 4 [/SUP], James Wilton[SUP] 1 [/SUP], Jason Wong[SUP] 4 [/SUP], Troy Grennan[SUP] 4 [/SUP], Catherine Chambers[SUP] 5 [/SUP], Abigail Kroch[SUP] 6 [/SUP], Cecilia T Costiniuk[SUP] 7 [/SUP], Curtis L Cooper[SUP] 8 [/SUP], Ann N Burchell[SUP] 9 [/SUP], Aslam Anis[SUP] 10 [/SUP]
Affiliations
- PMID: 36462571
- DOI: 10.1016/j.ijid.2022.11.035
Abstract
Background: We estimated the effectiveness of COVID-19 vaccines against laboratory-confirmed SARS-CoV-2 infection among people living with HIV (PLWH) and compared estimates with a matched HIV-negative cohort.
Method: We used the British Columbia COVID-19 Cohort, a population-based data platform which integrates COVID-19 data on SARS-CoV-2 tests, laboratory-confirmed cases, and immunizations with provincial health services data. Vaccine effectiveness (VE) was estimated with a test-negative design using multivariable logistic regression.
Results: Adjusted VE against SARS-CoV-2 infection was 79.2% (52.5, 90.9%) 7-59 days after two doses, rising to 91.6% (75.2, 97.2%) between 60-89 days. VE was preserved four to six months following receipt of 2 doses after which slight waning was observed (72.7% [39.1, 87.8%]). In the matched cohort (n=375 043), VE peaked at 91.0% (90.5, 91.5%) 7-59 days after 2 doses and was sustained for up to four months after which evidence of waning was observed, dropping to 83.8% (82.9, 84.7%) between four to six months.
Conclusion: Receipt of two COVID-19 vaccines doses was effective against SARS-CoV-2 infection among PLWH pre-Omicron. VE estimates appeared to peak later in PLWH compared to the matched HIV-negative cohort and the degree of waning was relatively quicker in PLWH; however, overall estimates were comparable in both populations.
Keywords: Canada; Coronavirus disease; HIV; SARS-CoV-2; Vaccine Effectiveness.